Last reviewed · How we verify
NCT04515043
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
Phase 1 trial testing INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study. in Solid Tumor, Adult in 6 participants. Completed in 19 December 2020.
19 December 2020
Quick facts
| Lead sponsor | Invectys |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 6 |
| Start date | 16 October 2020 |
| Primary completion | 19 December 2020 |
| Estimated completion | 19 December 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study. — full drug profile →
Conditions studied
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Sponsor
Invectys — full company profile →
Who can join
18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical research progress of telomerase targeted cancer immunotherapy: a literature review.
Wang Y, Zhang X, Chen G, Shao M. · · 2024 · cited 6× · PMID 39145070 · DOI 10.21037/tcr-24-196 -
Antibiotic-Free Gene Vectors: A 25-Year Journey to Clinical Trials.
Marie C, Scherman D. · · 2024 · cited 6× · PMID 38540320 · DOI 10.3390/genes15030261 -
Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics.
Tao HY, Zhao CY, Wang Y, Sheng WJ, et al · · 2024 · cited 5× · PMID 38708177 · DOI 10.2147/ijn.s448556
Verify or expand the search:
- PubMed search for NCT04515043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor, Adult
Currently open trials in the same condition.
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
Other Invectys trials
Trials by the same sponsor.
- NCT03265717 — DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04515043 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Invectys
- Last refreshed: 1 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04515043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing